Bajaj Healthcare launches ‘Posaconazole API’ used for treating Mucormycosis infection

28 May 2021 Evaluate

Bajaj Healthcare has launched ‘Posaconazole API’ used in treating Mucormycosis (Black Fungus) infection in Covid-19 patients. The company has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market ‘Posaconazole API’ as approved medication for treating Mucormycosis in India and it will commence its commercial production from first week of June 2021.

Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post Covid complications. Black fungus is a deadly fungal infection and has triggered a new health challenge in the country. More than 11,000 cases of black fungal infection have been reported from different parts, forcing state governments to declare it an epidemic.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

298.80 9.05 (3.12%)
07-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1507.00
Dr. Reddys Lab 6037.55
Cipla 1497.30
Zydus Lifesciences 1058.45
Lupin 1630.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.